Interestingly, IL-6 targeting by antibodies was found to induce synergistic T cell killing effects when combined with T cell immunoglobulin and mucin-domain containing-3, also known as HAVCR2 receptor (TIM-3/ HAVCR2) therapy, in animal cancer models [77]. This evidence concerns the gene IL6 and cancer.